Emulating the natural timing of dopamine receptor activation in Parkinson's Disease

被引：0
|
作者：
Reynolds, J.
Hyland, B.
Wickens, J.
Tan, E.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
225
引用
收藏
页码：S99 / S99
页数：1
相关论文
共 50 条
  • [31] Role of dopamine receptor agonists in the treatment of early Parkinson's disease
    Bonuccelli, Ubaldo
    Del Dotto, Paolo
    Rascol, Olivier
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S44 - S53
  • [32] Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson’s Disease
    Manuela Contin
    Roberto Riva
    Fiorenzo Albani
    Agostino Baruzzi
    CNS Drugs, 2000, 14 : 439 - 455
  • [33] Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease
    Jenner, P
    CURRENT OPINION IN NEUROLOGY, 2003, 16 : S3 - S7
  • [34] Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's Disease
    Perez-Lloret, Santiago
    Rascol, Olivier
    CNS DRUGS, 2010, 24 (11) : 941 - 968
  • [35] Dopamine receptor agonists: more adverse events in Parkinson's disease
    Reactions Weekly, 2001, 864 (1) : 6 - 6
  • [36] Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease
    Morelli, M.
    Simola, N.
    Carta, A. R.
    Tronci, E.
    Pinna, A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 248 (1-2) : 283 - 283
  • [37] Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease
    Wang, J
    Zhao, CY
    Chen, B
    Liu, ZL
    NEUROSCIENCE LETTERS, 2004, 355 (03) : 193 - 196
  • [38] Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease
    Fedorova N.V.
    Chigir' I.P.
    Neuroscience and Behavioral Physiology, 2007, 37 (6) : 539 - 546
  • [39] Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease
    Contin, M
    Riva, R
    Albani, F
    Baruzzi, A
    CNS DRUGS, 2000, 14 (06) : 439 - 455
  • [40] The role of D1 dopamine receptor activation in Parkinson's disease: insight from apomorphine and other clinically used dopamine agonists
    Mailman, R. B.
    Heinzen, E.
    Huang, X.
    MOVEMENT DISORDERS, 2006, 21 : S643 - S643
12345